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Abstract 
Background:  Toll-like receptors (TLRs) are the major pattern recognition receptors that mediate sensing of a wide 
range of microorganisms. TLR2 forms heterodimers with either TLR1 or TLR6, broadening its ligand diversity against 
pathogens. TLR1, TLR2 and TLR6 have been implicated in the recognition of Candida albicans, an opportunistic fungal 
pathogen that colonizes the gastrointestinal tract. In this study, we explored whether the deficiency in TLR1, TLR2 or 
TLR6 impacts C. albicans colonization and inflammation-associated colonic injury in the dextran sulfate sodium (DSS)-
induced colitis in mice.
Results: DSS treatment and C. albicans challenge induced greater weight loss, worse clinical signs of inflammation, 
higher histopathologic scores, and increased mortality rates in TLR1−/− and TLR2−/− mice when compared to TLR6−/− 
and wild-type mice. The number of C. albicans colonies in the stomach, colon and feces was decreased in TLR6−/− 
mice as compared to TLR2−/−, TLR1−/− and wild-type mice. Interestingly, the population of E. coli in colonic luminal 
contents, intestinal permeability to FITC-dextran and cytokine expression were significantly increased in TLR1−/− and 
TLR2−/− mice, while they were decreased in TLR6−/− mice.
Conclusion: In contrast to TLR6, both TLR1 and TLR2 deficiencies increased intestinal inflammation, and the over-
growth of C. albicans and E. coli populations in the colitis model, suggesting the involvement of TLR1 and TLR2 in 
epithelial homeostasis, and a role of TLR6 in increasing intestinal inflammation in response to pathogen-sensing.
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Background
Toll-like receptors (TLRs) are the main family of pattern 
recognition receptors (PRRs) through which immune and 
non-immune cells sense pathogen-associated molecu-
lar patterns (PAMPs) [1, 2]. Several TLRs are implicated 
in the recognition of fungal pathogens such as Candida 
albicans [3, 4]. The interaction between TLRs and yeasts 
during candidiasis stimulates immune cells to generate 
inflammatory and immunomodulatory mediators that 
shape the host immune response. Unlike TLR4, TLR2 
recognizes both blastoconidia and hyphal forms of C. 
albicans [5]. TLR2 forms heterodimers with either TLR1 
or TLR6 which have been implicated in ligand discrimi-
nation [6]. TLR2 senses phospholipomannans, which 
are expressed in the cell wall of C. albicans [7]. In addi-
tion, TLR2 in combination with galectin-3 also senses 
β-mannosides [8].
TLRs are expressed not only in myeloid cells and leu-
kocytes, but also in the intestinal epithelium, which 
contributes to mucosal homeostasis by preventing the 
penetration of commensal microbiota into the intestine 
[9, 10]. In an animal model of colitis, TLR2−/− mice 
developed more severe colonic inflammation than 
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wild-type mice [11]. Moreover, mutations in TLRs, 
including the TLR2 gene, have been associated with 
predisposition to and maintenance of inflammatory 
bowel disease (IBD) [12–14]. Interestingly, in patients 
with ulcerative colitis, Pierik et  al. [15] observed an 
association between TLR1 and TLR2 gene polymor-
phisms and pancolitis, and a negative relationship 
between TLR6 polymorphisms and pancolitis, suggest-
ing that TLR2 and its co-receptors TLR1 and TLR6 are 
involved in the initial immune response to pathogens in 
the development of IBD.
The aim of this study was to determine the impact 
of TLR1, TLR2, and TLR6 deficiency on inflammatory 
parameters associated with C. albicans colonization 
and acute colitis induced by DSS by comparing wild-
type, TLR1−/−, TLR2−/−, and TLR6−/− mice. We also 
assessed intestinal permeability, serological response, 
and colonic expression levels of pro-inflammatory 
and anti-inflammatory cytokines in control and TLR-
deficient mice. Finally, we explored the effects of 
TLR deficiency on neutrophil-mediated C. albicans 
phagocytosis/death.
Results
Candida albicans CFU in stools and mouse body weight
TLR1−/−, TLR2−/−, TLR6−/−, and wild-type mice were 
challenged with a single oral inoculum of C. albicans 
(107 CFU) and the amount of yeast in stool samples was 
analyzed daily for 2 weeks to assess the colonization rate 
(Fig.  1a). C. albicans colonization was not observed in 
any of these mice a few days later. In the absence of DSS, 
no significant differences in body weight were observed 
between TLR deficient mice and wild-type mice that 
received C. albicans (Fig.  1b). Additionally, there were 
no differences between wild-type and TLR deficient mice 
that challenged with C. albicans in terms of clinical and 
histological scores (data not shown).
Mouse weight and survival analysis in DSS‑induced murine 
colitis
To assess the association between TLR1, TLR2 or 
TLR6 deficiency and C. albicans colonization in DSS-
induced murine colitis, mice were monitored daily for 
2  weeks for body weight loss and survival after a sin-
gle oral challenge with C. albicans and DSS treatment 
(Fig.  2a). All mice treated with DSS showed signifi-
cant body weight loss, and no mortality was observed. 
Interestingly, C. albicans colonization caused a greater 
body weight loss in TLR1−/− and TLR2−/− DSS mice 
when compared to TLR6−/− and wild-type DSS-treated 
mice (Fig. 2b–d). From day 9, when compared to wild-
type mice treated with C. albicans and DSS, there was 
a significant decrease in body weight of TLR1−/− and 
TLR2−/− mice treated with C. albicans and DSS. Fur-
thermore, the C. albicans and DSS-treated mouse sur-
vival rate was lower in TLR1−/− and TLR2−/− mice 
(86% survival) than in TLR6−/− and wild-type mice 
(93% survival) (Fig. 2e).
Clinical and histologic inflammation scores
To evaluate clinical inflammation scores, mice were 
monitored daily using the parameters of stool con-
sistency and the presence or absence of faecal blood 
(Fig.  2f ). In the absence of C. albicans challenge, no 
significant difference in clinical scores for inflamma-
tion was observed between DSS-treated TLR6−/− and 
DSS-treated wild-type mice. In contrast, clinical scores 
for inflammation were significantly higher in TLR1−/− 
and TLR2−/− mice than in wild-type DSS-treated mice. 
Importantly, the clinical symptoms of colitis, such as 
diarrhea and bloody stools, appeared more rapidly 
in TLR1−/− and TLR2−/− mice than in wild-type and 
TLR6−/− C. albicans and DSS-treated mice. Micro-
scopic inflammatory changes were also assessed in mice 
Fig. 1 Candida albicans colonization and body weight in mice chal-
lenged with C. albicans. a Number of C. albicans colony forming units 
(CFU) recovered from stools. A single inoculum of 107 C. albicans was 
administered to mice on day 1. A total of 40 mice were divided into 
four groups composed of wild-type Candida (WT, n = 10), TLR1−/− 
Candida (n = 10), TLR2−/− Candida (n = 10), and TLR6−/− Candida 
(n = 10). Data are mean ± SE of two independent experiments.  
b Mouse body weight. There were no differences between wild-type 
and TLR deficient mice in terms of body weight changes. Data are 
mean ± SE of two independent experiments
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colons (Fig.  2g). All surviving animals were sacrificed 
on day 14 and histologic injury scoring was performed 
on the colons. Histologic scores, based on the extent 
of infiltration of inflammatory cells and the degree 
of tissue damage, ranged from 0 to 6, and reflected 
inflammation and crypt damage caused by DSS. No sig-
nificant difference in the histologic score was detected 
between wild-type and TLR-deficient DSS-treated 
mice. In contrast, histologic scores were substantially 
higher in C. albicans and DSS-treated TLR1−/− and 
Fig. 2 Increased morbidity and mortality of TLR1−/− and TLR2−/− mice due to C. albicans and DSS-induced colitis. a Schematic representation of 
the experimental procedure. A single inoculum of 107 C. albicans was administered to mice on day 1 and low doses of DSS (1.5%) were given in the 
drinking water for 2 weeks. A total of 120 mice were divided into eight groups composed of wild-type DSS (WT D, n = 10), wild-type C. albicans and 
DSS (WT CaD, n = 20), TLR1−/− D (n = 10), TLR1−/− CaD (n = 20), TLR2−/− D (n = 10), TLR2−/− CaD (n = 20), TLR6−/− D (n = 10), and TLR6−/− CaD 
(n = 20) mice. b–d Mouse body weight. Data are the mean ± SE of two independent experiments. +P<0.05 for TLR-deficient CaD mice versus 
wild-type D mice. *P < 0.05 for TLR-deficient CaD mice versus wild-type CaD mice. e Mouse survival. Results are expressed as percent survival from 
the time of C. albicans challenge and DSS treatment. The survival data were significantly different by the log-rank test (P < 0.05). f Clinical analysis of 
DSS-induced colitis in mice. Clinical score was determined by assessing weight loss, change in stool consistency and presence of gross bleeding. 
The clinical score ranged from 0 to 8 (each value corresponds to the mean value of 14 days per group). +P<0.05 for TLR1−/− DSS (d) and TLR2−/− D 
mice versus wild-type (WT) D mice; and *P < 0.05 for TLR1−/− C. albicans and DSS (CaD) and TLR2−/− CaD mice versus wild-type CaD mice.  
g Histologic scores. Mice were exposed to 1.5% DSS in drinking water for 14 days. Scores range from 0 (no changes) to 6 (extensive cell infiltration 
and tissue damage). *P < 0.05 for TLR1−/− CaD and TLR2−/− CaD mice versus wild-type CaD mice
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TLR2−/− as compared to TLR6−/− and wild-type mice 
(P  <  0.05). Epithelial damage occurred throughout the 
colonic mucosa, and the infiltrated cells were mostly 
polynuclear (Fig. 3). In addition, cryptic abscesses and 
mucosal edema was more frequently observed in the 
colons of TLR1−/− and TLR2−/− mice than in those of 
TLR6−/− and wild-type C. albicans and DSS-treated 
mice (Fig. 3).
Effects of DSS‑induced colitis on C. albicans colonization
Mice were challenged with a single oral inoculum of 
C. albicans (107  CFU) and given 1.5% DSS in drink-
ing water for 14 days (Fig. 4a). Despite a trend towards 
higher number of C. albicans CFUs in the stools of 
TLR1−/− mice, there was no significant difference 
between wild-type, TLR1−/−, and TLR2−/− mice during 
the entire observation period. In contrast, the number 
of C. albicans CFUs strongly decreased in the stools of 
TLR6−/− mice on day 7 after challenge, and remained 
significantly lower than that of wild-type mice up to 
day 13 (P < 0.05).
To evaluate C. albicans colonization in the gut, the 
number of yeasts adhering to the stomach and colon 
was determined (Fig.  4b, c). Significantly higher 
numbers of CFUs were observed in the stomach of 
TLR1−/− mice when compared to TLR2−/−, TLR6−/−, 
Fig. 3 Histologic analysis of the colon in C. albicans and DSS-induced colitis. a, c correspond to colon sections from wild-type mice receiving water 
as controls (CTL), and C. albicans (Ca) respectively. e, g, i, and k correspond to colon sections from wild-type C. albicans and DSS (CaD), TLR1−/− CaD, 
TLR2−/− CaD, and TLR6−/− CaD mice, respectively. In the absence of DSS, no significant differences in the colon sections were observed between 
control animals (not inoculated) and those that received C. albicans (a, c). The colon sections from wild-type CaD and TLR6−/− CaD mice show an 
inflammatory cell infiltrate in colonic wall structures (b, h). The colon sections from TLR1−/− CaD and TLR2−/− CaD mice display a high inflammatory 
cell infiltrate in colonic wall structures and massive tissue destruction (asterisk, h, j). The scale bars represent 50 µm (a, c, e, g, i, k) and 10 µm  
(b, d, f, h, j l)
Page 5 of 13Choteau et al. Gut Pathog  (2017) 9:9 
and wild-type mice (P < 0.001). C. albicans did not dis-
seminate to the lungs, heart, liver, spleen or kidneys of 
wild-type and TLR deficient mice (data not shown).
Serologic analysis and intestinal permeability
To evaluate the association between anti-mannan 
antibody titers, C. albicans colonization, and TLR 
deficiency in DSS-treated mice, we assessed man-
nanemia, which correlates to mannan levels in the 
blood (Fig.  4d). Mannanemia was higher in TLR1−/− 
and TLR2−/− mice as compared to wild-type C. 
albicans and DSS-treated mice (P < 0.05), which cor-
related with the higher clinical and histologic scores 
for inflammation in TLR1−/− and TLR2−/− mice. 
Additionally, mannanemia was significantly lower 
in TLR6−/− than that of wild-type mice (P  <  0.05). 
Next, we assessed the in  vivo intestinal permeabil-
ity using fluorescein isothiocyanate (FITC)-dextran 
(Fig. 4e). Intestinal permeability of FITC-dextran was 
significantly increased in TLR1−/− and TLR2−/− as 
compared to TLR6−/− and wild-type C. albicans and 
DSS-treated mice (P  <  0.05). A damaged intestinal 
barrier in TLR1−/− and TLR2−/− mice following C. 
albicans colonization and DSS treatment is also con-
sistent with the clinical symptoms and severe epithe-
lial damage in the colons of these mice.
Effects of DSS‑induced colitis and C. albicans colonization 
on the growth of the E. coli population
To assess the impact of DSS-induced colitis and C. albi-
cans colonization on the growth of the E. coli popula-
tion, the colonic luminal contents were analyzed at day 
14 in all groups. We found that C. albicans alone did 
not induce any changes in the E. coli population. How-
ever, DSS-induced colitis promoted an increased E. coli 
population in TLR1−/−, TLR2−/− and wild-type mice, 
but a decrease in TLR6−/− mice, regardless of C. albi-
cans colonization (Fig. 5).
Colonic expression levels of cytokines
IL-1β and TNF are major pro-inflammatory cytokines 
that are rapidly released after tissue injury and fun-
gal infection, so we determined their expression levels 
in the colons of mice challenged with C. albicans and 
treated with DSS (Fig.  6a–d). Both the mRNA expres-
sion levels and protein levels of IL-1β and TNF were 
significantly increased in the colons of TLR1−/− and 
TLR2−/− mice, whereas their expression levels were sig-
nificantly reduced in TLR6−/− mice when compared to 
wild-type mice (P < 0.05). Interestingly, both TLR1−/− 
and TLR2−/− mice had higher expression levels of IL-10 
and IL-17A when compared to TLR6−/− and wild-type 
mice (Figs. 5f, 6e, P < 0.05).
Fig. 4 Candida albicans colonization in mouse DSS-induced colitis. 
a Number of C. albicans colony forming units (CFU) recovered from 
stools. Data are the mean ± SD of 20 mice per group. *P < 0.05 for 
TLR6−/− C. albicans and DSS (CaD) mice versus wild-type (WT) CaD 
mice. b, c Number of C. albicans CFU recovered from the stomach 
and colon. Data are the mean ± SD of 20 mice per group (P < 0.001). 
d Mannan levels in the serum of wild-type, TLR1−/−, TLR2−/−, and 
TLR6−/− CaD mice. *P < 0.05 for TLR1−/− CaD, TLR2−/− CaDSS and 
TLR6−/− CaD mice versus wild-type CaDSS mice. e FITC-dextran 
permeability in the colons of mice. Mice were given FITC-dextran by 
gavage (500 mg/kg body weight). After 4 h, blood samples were col-
lected and fluorescence levels were measured. *P < 0.05 for TLR1−/− 
CaD, and TLR2−/− CaD mice versus wild-type CaD mice
Fig. 5 Escherichia coli overgrowth in DSS-induced colitis. Four groups 
composed of controls (water), C. albicans alone (Ca), DSS alone (D), 
and C. albicans + DSS (CaD). Data are the mean ± SD of 10 mice 
per group (P < 0.001 for TLR1−/−, TLR2−/−, or wild-type mice versus 
TLR6−/− mice)
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Impact of TLR1, TLR2, or TLR6 deficiency 
on neutrophil‑mediated C. albicans phagocytosis 
and death
Neutrophils are essential phagocytic cells involved 
in antifungal immunity. Therefore, we assessed the 
phagocytic activity of thioglycolate-elicited neutrophils 
from TLR1−/−, TLR2−/−, TLR6−/−, and wild-type mice 
(Fig. 7a). Neutrophils and germinated C. albicans were 
co-incubated for 2  h, and the number of viable fungi 
was quantified every 30  min. We did not find any sig-
nificant differences in C. albicans death. Additionally, 
live cell video microscopy showed no differences in 
the engulfment of C. albicans by TLR1−/−, TLR2−/−, 
TLR6−/−, and wild-type neutrophils (data not shown). 
To examine whether neutrophils utilize TLR1, TLR2, 
or TLR6 for adhesion to C. albicans, we quantified the 
CFUs of C. albicans after 1  h of co-incubation with 
neutrophils (Fig.  7b). Neutrophils from TLR1−/− and 
TLR2−/− mice showed significantly less adherence to 
C. albicans than those from TLR6−/− and wild-type 
mice (P < 0.05). We also assessed the migration of neu-
trophils towards germinated C. albicans cells after 8 h 
of co-incubation using a transwell assay (Fig.  7c). We 
observed less TLR1−/− and TLR2−/− neutrophil migra-
tion towards C. albicans than TLR6−/− and wild-type 
neutrophil migration (P < 0.05).
Fig. 6 Cytokine expression in C. albicans and DSS-induced colitis. a, b Relative expression levels of TNF, and IL-1β mRNA in mouse colons.  
c, d Protein levels of TNF, and IL-1β in mouse colons. e, f Relative expression levels of IL-17, and IL-10 mRNA in mouse colons. Data are the 
mean ± SE of 20 mice per group (P < 0.05). *P < 0.05 for TLR1−/−, TLR2−/−, or TLR6−/− CaD mice versus wild-type (WT) CaD mice. θP < 0.05 for 
TLR6−/− CaD mice versus TLR1−/− CaD mice, εP < 0.05 for TLR6−/− CaD mice versus TLR2−/− CaD mice, +P<0.05 for TLR2−/− CaD mice versus 
TLR1−/− CaD mice
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Discussion
IBD is characterized by microbial dysbiosis related to the 
abundance of a range of pathogenic microbial species, 
in particular, C. albicans [16–18]. C. albicans coloniza-
tion is more frequent and more severe in patients with 
Crohn’s disease than in control subjects [19]. The abun-
dance of yeast in the gut can cause inflammation by acti-
vating cells through PRRs, including TLRs [20, 21]. TLRs 
are highly expressed in mucosal immune and epithe-
lial cells and their triggering stimulates cytokine release 
and microbicidal activity [22]. In the present study, we 
investigated the role of TLR1, TLR2, and TLR6 in intes-
tinal inflammation and C. albicans colonization. We 
previously developed a C. albicans colonization model, 
which is promoted by intestinal inflammation induced 
by DSS [23]. This C. albicans colonization is not main-
tained without the presence of intestinal inflammation; 
otherwise C. albicans is eliminated immediately in mice. 
In this DSS model, we employed a low concentration of 
DSS (1.5%) to promote C. albicans colonization with-
out inducing mouse mortality or severe colitis. In the 
present study, we compared DSS mice and mice treated 
with DSS and colonized with C. albicans. Initially, we 
performed experiments without DSS by administer-
ing C. albicans only to mice used as controls (TLR1−/−, 
TLR2−/−, TLR6−/−, and wild-type mice). No C. albi-
cans colonization was observed in any of these mouse 
strains a few days later. Interestingly, we observed that 
TLR1−/− and TLR2−/− mice were more susceptible to 
DSS-induced colitis than TLR6−/− and wild-type mice. 
Rakoff-Nahoum et al. [10] demonstrated that mice defi-
cient in TLR2 are highly susceptible to DSS-induced 
colitis, suggesting that TLRs contribute to prevent an 
aberrant immune response against the commensal flora. 
TLR2 forms heterodimers with either TLR1 or TLR6 
to recognize different configurations of lipoproteins/
lipopeptides [6]. It has been reported that TLR2/TLR6 
recognizes yeast-derived zymosan, which is mainly com-
posed of mannans and β-glucans [24]. Jouault et al. [7, 8] 
showed that TLR2 binds to phospholipomannans of C. 
albicans in the presence of galectin-3, and β-mannosides 
of C. albicans, to induce pro-inflammatory responses by 
macrophages. TLR2 can also collaborate with dectin-1 to 
bind fungal β-glucans [25, 26].
We observed that C. albicans colonization enhances 
the susceptibility of TLR1−/− and TLR2−/− mice, but not 
Fig. 7 Cell death, adhesion, and migration of neutrophils against C. albicans. a Cell death assay. 105 C. albicans cells were suspended in RPMI and 
mixed with 5 × 105 neutrophils. C. albicans was counted every 30 min. Results are expressed as percent death. b Adhesion of neutrophils to C. 
albicans. C. albicans yeasts were incubated for 1 h with neutrophils. Results are expressed as percent neutrophils adhering to yeasts. *P < 0.05 for 
TLR1−/−, and TLR2−/− neutrophils versus wild-type (WT) neutrophils. c Migration of neutrophils towards C. albicans. The migration of neutrophils 
towards C. albicans was performed using a transwell assay. Results are expressed as the percent neutrophils migrating from the upper to the lower 
chamber. Data are the mean ± SE of three independent experiments (P < 0.05). *P < 0.05 for TLR1−/−, and TLR2−/− neutrophils versus wild-type 
neutrophils
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TLR6−/− mice, to intestinal inflammation. TLR6−/− mice 
were more resistant to DSS-induced colitis as reflected by 
lower clinical and histologic scores for inflammation and 
mortality. These data corroborate findings from a recent 
study which showed that mice deficient in TLR6−/− are 
protected from intestinal inflammation and have a low 
number of Th17 cells [27]. This evidence emphasizes the 
role played by TLR6 in the induction of an inflammatory 
response to C. albicans sensing. Netea et al. [28] showed 
that, in contrast to TLR1, TLR6 is involved in the rec-
ognition of C. albicans and modulation of the Th1/Th2 
cytokine balance. Moreover, TLR2−/− mice had signifi-
cantly impaired survival to Candida infection, indicating 
that TLR2 confers protection against primary dissemi-
nated candidiasis [3].
All TLRs except TLR3 are expressed by neutrophils, 
which represent the primary first line of defense against 
C. albicans infection [1, 29]. In the present study, neutro-
phils from TLR1, TLR2, and TLR6 deficient mice were 
not affected in terms of C. albicans phagocytosis. On the 
other hand, adhesion and migration of neutrophils from 
TLR1−/− and TLR2−/− mice to C. albicans was impaired. 
In line with these findings, neutrophils and macrophages 
from TLR2−/− mice internalized and killed C. albicans as 
efficiently as wild-type cells [4]. Moreover, Weindl et al. 
[30] showed neutrophil-dependent TLR4-mediated pro-
tective mechanisms against C. albicans infection at epi-
thelial surfaces, a phenomenon that was independent of 
neutrophil migration to C. albicans or epithelial cells.
Analysis of colon cytokine expression revealed that 
TLR1 deficiency strongly up-regulated TNF, IL-1β, and 
IL17A, whereas TLR6 deletion down-regulated TNF, 
IL-1β, and IL17A colonic expression when compared to 
controls. These data suggest that TLR1 plays a role in 
dampening the cytokine response and preventing exces-
sive immune-mediated tissue damage, whereas TLR6 
is involved in exacerbating the inflammatory response 
associated with tissue damage upon recognition of C. 
albicans and DSS-induced colitis [31, 32]. Notably, C. 
albicans colonization increased TLR2 expression in the 
colons of DSS-treated wild-type mice, whereas TLR2 
expression was reduced in galectin-3 deficient mice lead-
ing to high pro-inflammatory cytokine expression and 
aggravated intestinal inflammation [20].
IL-10 is essential for host defense against C. albicans 
infection and can limit the potential tissue damage 
caused by inflammation [33]. In the present study, we 
showed that in contrast to the state of TLR6−/− mice, 
DSS-induced colitis induced the production of pro- 
and anti-inflammatory cytokines, including IL-10, in 
TLR1−/− mice. In line with this study, the absence of 
TLR6 dramatically increased survival and decreased 
IL-10 production, whereas the absence of TLR1 led 
to decreased survival and higher IL-10 levels in mice 
infected with Yersinia pestis, suggesting that TLR6 
is a distinct TLR receptor driving regulatory IL-10 
responses [34]. Netea et al. [35] showed that TLR acti-
vation, in particular TLR2, can suppress the immune 
defense against C. albicans through the induction of 
IL-10 and regulatory T-cells.
In this study, we observed that TLR6−/− mice elimi-
nate C. albicans from the digestive tract more rapidly 
than TLR1−/− and TLR2−/− mice. In particular, colo-
nization in the stomach was dramatically higher in 
TLR1−/− mice, supporting the notion of a protective 
role of TLR1 and TLR2 against C. albicans coloniza-
tion. Additionally, in agreement with our results, TLR1 
gene polymorphisms have been associated with an 
increased susceptibility to candidemia in patients [21]. 
In addition, polymorphisms in the TLR2 gene have 
been identified as a risk factor for candidemia [36, 37]. 
Although TLR2 interacts with a large number of non-
TLR molecules, in particular Galectin-3 and Dectin-
1-mediated ERK/MAPK activation [8, 25], allowing the 
recognition of fungal ligand varieties, in our study, we 
found that mice deficient in TLR1 had higher levels of 
colonization with C. albicans in the stomach and colon 
than TLR2−/− mice. These data show that TLR1 is more 
involved in C. albicans elimination from the gut than 
TLR2, suggesting that the absence of TLR1 can have 
a great impact on the formation of the heterodimer 
TLR1/TLR2 when compared to the absence of TLR2. 
Van Duin et  al. [38] showed that alterations in base-
line TLR1 surface expression were increased in elderly 
individuals, whereas TLR2 surface expression was unaf-
fected, suggesting that the defect in TLR1 expression 
can contribute to the increased infection-related mor-
bidity and mortality observed in elderly individuals.
Changes in commensal bacterial diversity can differ-
entially modulate mucosal TLR responsiveness, lead-
ing to TLR-mediated hyper- or hypo-reactive immune 
responses [10, 39, 40]. In the present study, intestinal 
inflammation alone was sufficient to promote the over-
growth of E. coli. Additionally, both inflammation and C. 
albicans colonization maintained E. coli overgrowth in 
TLR1−/−, TLR2−/− and wild-type mice when compared 
to that in TLR6−/− mice. These data are consistent with 
Lupp et  al. [41] finding which suggested that the com-
mensal E. coli increased during colitis and displayed a 
strong pro-inflammatory potential. Ey et al. [14] showed 
that an unaltered microbiota was required for colitis 
exacerbation in TLR2/MDR1A double-knockout mice 
once protection from colitis was observed upon antibi-
otic treatment.
In the present study, intestinal inflammation alone was 
sufficient to promote the overgrowth of E. coli. Additionally, 
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both inflammation and C. albicans colonization main-
tained E. coli overgrowth in TLR1−/−, TLR2−/− and wild-
type mice when compared to that in TLR6−/− mice. These 
data are consistent with Lupp et al. [41] finding which sug-
gested that the commensal E. coli increased during colitis 
and displayed a strong pro-inflammatory potential.
Experimental and clinical studies emphasize the role 
of the serologic response during the development of 
IBD [20, 42]. Crohn’s disease patients who express high 
levels of serologic markers experience more aggressive 
disease, suggesting that the presence of Crohn’s disease 
marker antibodies reflect a specific mucosal immune-
mediated response [43]. We observed that mannanemia 
was elevated only in TLR1−/− and TLR2−/− mice. High 
mannanemia in TLR1−/− and TLR2−/− mice was corre-
lated with increased intestinal permeability, which facili-
tates the passage of fungi into the bloodstream. Clinically, 
Pierik et al. [15] showed a negative association between 
TLR6 S249P and ulcerative colitis with proctitis. In our 
study, we found in a clinical cohort of 26 healthy subjects 
(between 25- and 65-years-old) an association between 
the TLR6 rs5743810 homozygous wild-type genotype 
and ASCA (anti-Saccharomyces cerevisiae antibody) level 
(P  =   0.0317). Homozygous healthy subjects (TLR6 A/A 
wild-type) have significantly higher ASCA levels than 
heterozygous (TLR6 A/G) and homozygous mutants 
(TLR6 G/G) indicating a possible association of this 
TLR6 rs5743810 polymorphism with IBD (Additional 
file 1). These clinical data corroborate findings from our 
experimental study, which showed that deletion of TLR6 
decreased the circulating mannan level in mice. Taylor 
et al. [44] showed that among African Americans, women 
who carried 1 or 2 of the TLR6 rs5743810 alleles had 
decreased odds of endometritis and upper genital tract 
infection and there was a similar trend among white par-
ticipants. We intend to widen our study to larger groups 
of healthy subjects and patients with CD.
Conclusions
DSS-induced colitis promoted the overgrowth of E. coli 
and C. albicans in the gut. TLR1 and TLR6 had not the 
same effects on the TLR2-mediated immune response. 
Deletion of TLR1 exacerbated intestinal inflammation in 
response to C. albicans colonization, resulting in colonic 
injury and mouse mortality. Conversely, deletion of TLR6 
impacted on the intestinal inflammation via the modula-
tion of cytokine expressions and promoted the elimina-
tion of C. albicans. Overall, this study emphasizes the 
role of TLRs in the modulation of intestinal inflammation 
and C. albicans colonization and shows the involvement 
of TLR1 in the homeostasis of intestinal epithelium and 




Candida albicans Sc5314 strain was used throughout this 
study [45]. C. albicans isolates were grown in Sabouraud’s 
dextrose broth at 37 °C in a shaking incubator for 18 h.
Animals
Female C57BL/6 mice (8–10-weeks-old) were purchased 
from Charles River Laboratories (France). All mice were 
fed with a standard chow diet (Scientific Animal Food 
and Engineering, SAFE diet-A04, France). This diet con-
tained neither yeast cells nor yeast cell extract. The strain 
description and use of TLR1−/−, TLR2−/−, and TLR6−/− 
C57BL/6 mice has been provided elsewhere [46]. WT 
and TLRs−/− mice were each distributes into control 
group and experimental groups and two sets of experi-
ments (a total of 90 mice/experiment) were performed 
independently. A group of healthy mice was used as con-
trols (CTL, n = 5 WT and n = 15 TLR deficient mice). A 
second group of mice was gavaged orally with C. albicans 
without any other treatment (Ca, n = 10 WT and n = 30 
TLR deficient mice). A third group was treated with DSS 
alone (D, n =  10 WT and n =  30 TLR deficient mice). 
A fourth group was treated with DSS and gavaged orally 
with C. albicans (CaD, n = 20 WT and n = 60 TLR defi-
cient mice). Mouse survival and body weight were moni-
tored daily for 14 days. All efforts were made to minimize 
animal suffering. Mice with a body weight loss of >20% 
initial body weight were humanely euthanized by inhala-
tion of 5% isoflurane followed by cervical dislocation.
Inoculum preparation and induction of colitis
Each animal was inoculated on day 1 by single oral gav-
age with 200 µL of phosphate-buffered saline (PBS) con-
taining 107 C. albicans cells. Mice were then given 1.5% 
DSS (MW 36–50 kDa; MP Biomedicals, LLC, Germany) 
in drinking water from day 1 to day 14, to induce intes-
tinal inflammation. The presence of yeasts in the intesti-
nal tract was assessed daily by performing plate counts 
from feces (approximately 0.1 g/sample) [20]. Stool sam-
ples were daily collected from each tagged animal and 
suspended in 1  mL PBS, and plated onto Candi-Select 
medium (Bio-Rad, Marnes la Coquette, France). The col-
onies were counted after 48  h incubation at 37  °C. The 
results were noted as colony forming units (CFU)/µg of 
feces. To assess C. albicans colonization of the gut, the 
gastrointestinal tract was removed from sacrificed mice, 
and the stomach and colon were separated and ana-
lyzed. The tissues were cut longitudinally. After removal 
of intestinal contents, the tissues were washed several 
times with PBS to minimize surface contamination from 
organisms present in the lumen [47]. Serial dilutions of 
homogenates were plated onto Sabouraud’s agar plates, 
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and the results were expressed as C. albicans CFU/mg of 
tissue. For the E. coli identification, the colonic luminal 
faecal samples at 14 days were collected from each tagged 
animal and plated onto MacConkey agar (Sigma-Aldrich) 
containing Fluconazole (Fresenius Kabi, 60 mg/L) to sup-
press the growth of fungal cells. The plates were incu-
bated at 37  °C and examined at 24 and 48  h later. For 
the identification of bacteria, colonies were mixed with 
1.5  μL of matrix solution (α-cyano-4-hydroxycinnamic 
acid [HCCA]; Bruker Daltonics) dissolved in 50% ace-
tonitrile, 47.5% water, and 2.5% trifluoroacetic acid and 
allowed to dry prior to analysis using the MALDI-TOF 
MS (Microflex-Bruker Daltonics).
Assessment of clinical parameters
The body weight and mortality of the mice was recorded 
daily. The data were expressed as mean percent change 
from initial body weight. Clinical scores ranging from 0 
to 8 were calculated as described elsewhere [20, 48].
Intestinal permeability in vivo
Mice were given DX-4000-FITC (FD4000, Sigma-
Aldrich, France) by oral gavage (500 mg/kg body weight) 
[49]. After 4  h, blood samples were collected and DX-
4000-FITC concentrations were quantified with a 
Mithras® fluorescence spectrophotometer (Berthold 
technologies, France).
Histologic score
The rings of the transverse part of the colon were fixed 
overnight in 4% paraformaldehyde-acid, embedded in 
paraffin, and histological analysis was performed by 
staining the cross-sections (4-µm thick) with hematox-
ylin-eosin (Sigma-Aldrich, France). Histologic scores 
were evaluated by two independent blinded investiga-
tors who observed two sections per mouse at magnifi-
cations of ×10 and ×100. The scores were determined 
as described by Siegmund et  al. [48] and the sections 
were evaluated for the following two subscores: (1) a 
score for the presence and confluence of inflammatory 
cells, in the lamina propria and submucosa or trans-
mural extension; and (2) a score for epithelial damage, 
focal lymphoepithelial lesions, mucosal erosion and/
or ulceration and extension to the bowel wall. The two 
subscores were added together and the combined histo-
logic score ranged from 0 (no changes) to 6 (extensive 
cell infiltration and tissue damage). Immunohisto-
fluorescence staining of the colons was performed on 
dewaxed and PBS-rehydrated paraffin-embedded colon 
sections. The tissue sections were incubated for 30 min 
at room temperature in 1% bovine serum albumin 
(BSA) diluted in PBS. Slides were washed with PBS and 
incubated for 1 h at room temperature with anti-mouse 
CD281-TLR1 (eBioscience), anti-mouse CD282-TLR2 
(eBioscience), and anti-mouse TLR6 (ab37072, Abcam) 
antibodies, which were diluted 1:100 in PBS. After 3 
washes with PBS, the sections were incubated with 
fluorescein isothiocyanate-conjugated anti-rabbit or 
anti-rat antibodies (Zymed Laboratories) for 60  min 
at 37 °C [50]. The sections were then washed with PBS 
and counterstained with DAPI. The sections were then 
examined by confocal microscopy (Zeiss LSM710, 
diode 561 nm DPSS).
Measurement of mannan antigen in mouse serum
Mannan antigen was measured using a Platelia™ Can-
dida Ag (mannan) kit (Bio-Rad) according to the 
manufacturer’s instructions. Absorbance was read at 
450 nm (reference filter, 620 nm) in a microplate reader 
(Bio-Rad) after addition of tetramethylbenzydine [20]. 
Results were expressed as optical density (OD).
Real‑time mRNA quantification and measurement 
of cytokine levels in colons
Total RNA was isolated from colon samples using a 
NucleoSpin RNA II kit (Macherey–Nagel) follow-
ing the manufacturer’s instructions, with 20–50  units 
of DNase I (RNase-free) at 37  °C for 30  min to avoid 
contamination with genomic DNA. RNA was quanti-
fied with a Nanodrop (Thermo Scientific, Wilmington, 
DE). Reverse transcription of mRNA was carried out 
according to the manufacturer’s instructions (Applied 
Biosystems). Briefly, reverse transcription of mRNA 
was performed in a final volume of 20  μL, from 1  μg 
of total RNA, using 50  units of reverse transcriptase 
(Applied Biosystems) with 200 nmol oligo (dT) 12–18. 
Polymerase chain reaction (PCR) was then performed 
on this mixture using the one-step system (Applied 
Biosystems) with Fast SYBR green (Applied Biosys-
tems). Amplification was carried out in a total volume 
of 12  μL containing 0.25  μL of each primer (Table  1) 
and 2.5 μL of cDNA prepared as described above. SYBR 
green dye intensity was analyzed using step-one soft-
ware. All results were normalized to the reference gene 
POLR2A [51]. Cytokine concentrations from colons 
were measured using a commercial ELISA kit accord-
ing to the manufacturer’s instructions (eBioscience, San 
Diego, CA).
Adhesion, migration and phagocytosis
Mice were injected intraperitoneally with 500  µL ster-
ile thioglycolate (3%  wt/vol). After 6  h, mice were 
anaesthetized using 5% isoflurane and sacrificed by 
cervical dislocation. Neutrophils were collected by 
washing the peritoneal cavity with 5  mL of cold ster-
ile PBS [52]. Neutrophils were plated in RPMI medium 
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supplemented with 10% heat-inactivated fetal bovine 
serum (Gibco, France) and 1% penicillin–streptomy-
cin, and incubated for 1  h at 37  °C in 5% CO2. Non-
adherent cells were collected and centrifuged to isolate 
the neutrophil pellet. Viability and neutrophil counts 
were determined by the trypan blue exclusion method 
(Gibco, France).
Neutrophil adhesion assays were performed as 
described previously [53, 54]. Briefly, 96-well tissue 
culture plates (Corning) were pre-coated with polyvi-
nylpyrolidone (PVP, Sigma-Aldrich) and washed with 
PBS. Then, 104 C. albicans yeasts in 0.02 mL RPMI were 
added to each well and incubated overnight at 37 °C to 
germinate. To assess neutrophil adhesion to C. albicans, 
yeasts were incubated in YNB broth to prevent germi-
nation. The supernatant was removed after incubation, 
and adherent fungi were carefully washed with PBS. 
Approximately 5 × 104 calcein-labeled neutrophils were 
added to each well and the plates were then incubated 
at 37  °C for 1  h. After several washes, the percentage 
of adherent neutrophils was determined using a Mith-
ras® fluorometer. Neutrophil adhesion to PVP was sub-
tracted from that of the experimental samples. Results 
were expressed as percent adhesion. A migration assay 
was performed as described previously [53, 54]. Briefly, 
200  μL calcein-labeled washed neutrophils were added 
to the upper chamber of the transwell devices (Costar 
Transwell inserts in a 24-well plate format), and 600 μL 
RPMI with 106 C. albicans yeast was added to the lower 
chamber. Plates were placed in a humidified incuba-
tor at 37  °C and 5% CO2 for 8  h. To perform the cell 
death assay, 105 fungal cells were suspended in 0.2 mL 
RPMI, and mixed with 5 ×  105 (1:5 ratio) neutrophils. 
The neutrophil/fungus mixtures were incubated at 37 °C 
with slow shaking for 2  h. To determine the extent of 
cell death/phagocytosis, aliquots of the cell/fungal sus-
pension were taken every 30  min, diluted with PBS, 
and subsequently plated in serial dilutions on Sab-
ouraud’s dextrose agar plates. The neutrophils were not 
lysed before plating, and all fungal cells that remained 
ingested were recorded as “killed.”
Statistical analysis
 Data were expressed as the mean ±  SE of 20 mice in 
each group. Statistical analysis was performed with 
Prism 4.0 from GraphPad and XLSTAT. Data were ana-
lyzed using the Mann–Whitney U test to compare pairs 
of groups. The log-rank test was used to analyze mouse 
survival. Differences were considered significant when 
the P value was <0.05.
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